<DOC>
	<DOCNO>NCT00835640</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 180 mg Fexofenadine Hydrochloride tablet manufacture TEVA Pharmaceuticals Industries , Ltd. 180 mg ALLEGRAÂ® Tablets Aventis Pharmaceuticals , Inc. follow single oral dose ( 1 x 180 mg tablet ) healthy adult volunteer feed condition .</brief_summary>
	<brief_title>Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>All volunteer select study healthy , nonsmoking men woman 18 55 year age , inclusive , time dosing . The volunteer 's body mass index ( BMI ) less equal 30 . If female : Of child bear potential , practice acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence ; Is postmenopausal least 1 year ; Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstration positive hepatitis B surface antigen screen , hepatitis C antibody screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer currently breast feed . Female volunteer demonstrate positive pregnancy screen . Volunteers history allergic response ( ) fexofenadine relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers currently use report use tobacco nicotinecontaining product within 90 day prior Period I dose . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood four week complete study . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take prescription medication 14 day prior Period I dose , exception topical product without systemic absorption . Volunteers abnormal diet 28 day prior Period I dose . Volunteers report intolerance direct venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>